TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18822011

Group type: EXPERIMENTAL
Intervention: Microseal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lateral Compaction (LC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JS Quick‐Fill
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soft Core
Number of subjects: 60
Study: 16647911

Group type: EXPERIMENTAL
Intervention: Metronidazole vaginal gel (0.75%)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 12444307

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 6595

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6595
Study: 10196830

Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 824

Group type: COMPARATOR
Intervention: Conventional gold-alloy castings (Control)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Both titanium frameworks and control group
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Titanium frameworks
Number of subjects: 824
Study: 7594126

Group type: EXPERIMENTAL
Intervention: Usual-protein diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very-low-protein diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring of protein intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback by the dietitian
Number of subjects: 0
Study: 2339625

Group type: EXPERIMENTAL
Intervention: 1,25‐(OH)2D3 2 micrograms/day for 2 weeks before 3 months of sodium fluoride treatment 25 mg twice a day, in each 5‐month cycle
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) 25 mg twice a day with 1,25‐(OH)2D3 0.5 micrograms/day for 12 months in each 13‐month cycle
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) combined with calcium citrate for 12 months in each 13‐month cycle
Number of subjects: 71

Group type: COMPARATOR
Intervention: All groups (including sodium fluoride treatment)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sodium fluoride treatment
Number of subjects: 71
Study: 6107057

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.4‐0.8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzoctamine (10‐20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 0
Study: 30134428

Group type: EXPERIMENTAL
Intervention: Opt-out HIV screening during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat HIV testing in the third trimester
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid HIV screening during labor and delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linkage to ongoing care with HIV specialist
Number of subjects: 0
Study: 26824722

Group type: EXPERIMENTAL
Intervention: Self-manual lymph drainage (MLD) combined with physical exercise
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Physical exercise (PE) only
Number of subjects: 1000
Study: 25407038

Group type: EXPERIMENTAL
Intervention: Educational presentation on human trafficking (HT)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Delayed intervention comparison group
Number of subjects: 258
Study: 21614529

Group type: EXPERIMENTAL
Intervention: Experiencing threatening and deviant/violent life events
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Number of adverse life events experienced
Number of subjects: 515
Study: 20354472

Group type: EXPERIMENTAL
Intervention: ProDisc‐C cervical disc replacement (CDR)
Number of subjects: 164
Study: 17684166

Group type: EXPERIMENTAL
Intervention: Resiliency training classes
Number of subjects: 67

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 67
Study: 16218045

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/die
Number of subjects: 50
Study: 12119853

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9740203

Group type: EXPERIMENTAL
Intervention: High doses of zinc (1200 microg/kg, ratio 4:1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low doses of zinc (300 microg/kg, ratio 1:1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low zinc:iron intake with feeds
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High zinc:iron intake with feeds
Number of subjects: 14
Study: 8037087

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN) infusion at 10 to 60 micrograms/min for 1 hour, 2 days, or 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracoronary isosorbide dinitrate (ISDN) bolus (1 mg)
Number of subjects: 0
Study: 2659876

Group type: EXPERIMENTAL
Intervention: metoprolol (betaloc)
Number of subjects: 30

Group type: COMPARATOR
Intervention: propranolol (anaprilin)
Number of subjects: 30
Study: 29703802

Group type: EXPERIMENTAL
Intervention: Multicomponent early intervention program (home visits, baby massage, and parenting program)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 233
Study: 28969715

Group type: EXPERIMENTAL
Intervention: Annual treatment with IVM + ALB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biannual treatment with IVM + ALB (annual MDA followed by an additional MDA 6 months later)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entomological assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microfilaria prevalence assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community acceptability, feasibility and scale-up evaluation
Number of subjects: 0
Study: 25483772

Group type: EXPERIMENTAL
Intervention: Comprehensive school‐based health education programme (introducing healthy habits in the curriculum)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 509
Study: 24029871

Group type: EXPERIMENTAL
Intervention: Regular sodium diet (194±49 mmol Na/day) with lisinopril (40 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low sodium diet (102±52 mmol Na/day) with lisinopril (40 mg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Regular sodium diet (194±49 mmol Na/day) with lisinopril plus valsartan (320 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low sodium diet (102±52 mmol Na/day) with lisinopril plus valsartan (320 mg/day)
Number of subjects: 46
Study: 21393121

Group type: EXPERIMENTAL
Intervention: 28-item simplified food frequency questionnaire (SFFQ)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: SFFQ
Number of subjects: 81
Study: 19935615

Group type: EXPERIMENTAL
Intervention: Kimberly‐Clark warming system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard methods of control of body temperature
Number of subjects: 50
Study: 17073969

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional bare metal stents
Number of subjects: 0
Study: 15187504

Group type: EXPERIMENTAL
Intervention: AVP/NE infusion (4 units/hr)
Number of subjects: 38

Group type: COMPARATOR
Intervention: NE infusion only
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: AVP/NE infusion
Number of subjects: 38
Study: 10937036

Group type: EXPERIMENTAL
Intervention: Individualised physical activity advice from an exercise specialist
Number of subjects: 299

Group type: COMPARATOR
Intervention: No advice (control)
Number of subjects: 299
Study: 9065344

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Triprolidine hydrochloride 5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8091379

Group type: EXPERIMENTAL
Intervention: 100 mg dermatan sulfate (MF701) b.i.d.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 300 mg dermatan sulfate (MF701) b.i.d.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both dosages of dermatan sulfate (100 mg and 300 mg)
Number of subjects: 107
Study: 2517718

Group type: EXPERIMENTAL
Intervention: Prazosin therapy for one week
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Prazosin therapy during hyperosmolar mannitol load
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Prazosin therapy
Number of subjects: 21
Study: 1097597

Group type: EXPERIMENTAL
Intervention: Electrosleep treatment (24 live treatments)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study: 31761477

Group type: EXPERIMENTAL
Intervention: #Tamojunto program
Number of subjects: 6691
Study: 30711664

Group type: EXPERIMENTAL
Intervention: Brief online engagement-facilitation intervention (EFI) presented prior to an online self-help mental health program (myCompass)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Active online cognitive behavioral therapy (iCBT) intervention with EFI
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Active online cognitive behavioral therapy (iCBT) intervention without EFI
Number of subjects: 693

Group type: COMPARATOR
Intervention: Attention control group (arm 3)
Number of subjects: 693
Study: 26495881

Group type: EXPERIMENTAL
Intervention: Modified Dual Therapy (MDT) with amoxicillin 750 mg thrice daily plus rabeprazole 20 mg thrice daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard Quadruple Therapy (SQT) with rabeprazole 20 mg b.i.d., bismuth subcitrate 120 mg q.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard Quadruple Therapy (SQT)
Number of subjects: 200
Study: 24862395

Group type: EXPERIMENTAL
Intervention: PCPTRC 2.0 with percent free-PSA
Number of subjects: 5826

Group type: EXPERIMENTAL
Intervention: PCPTRC 2.0 without percent free-PSA
Number of subjects: 5826

Group type: COMPARATOR
Intervention: Placebo arm biopsies
Number of subjects: 5826
Study: 22950390

Group type: EXPERIMENTAL
Intervention: Phenylephrine at a dose of 0.3-0.4 μg.kg(‐1).min(‐1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dopamine and/or dobutamine at 2-8 μg.kg(‐1).min(‐1)
Number of subjects: 76
Study: 20538369

Group type: EXPERIMENTAL
Intervention: Standardized 3-item intimate partner violence screen, statements about the unacceptability of violence, risk assessment, and referral by a health professional research assistant
Number of subjects: 399

Group type: COMPARATOR
Intervention: Usual emergency health care
Number of subjects: 399
Study: 18594348

Group type: EXPERIMENTAL
Intervention: ssVEP testing
Number of subjects: 42

Group type: COMPARATOR
Intervention: psychophysical testing
Number of subjects: 42
Study: 16188156

Group type: EXPERIMENTAL
Intervention: Group A - 80 mg in one dose
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group B - repeated epirubicin 40 mg q wk x 4-8 sessions followed by q month to the end of the second year
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group C - 50 mg q month to the same duration
Number of subjects: 90
Study: 11923800

Group type: EXPERIMENTAL
Intervention: Aldosterone blockade (eplerenone)
Number of subjects: 6200
Study: 10845734

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 7625348

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (3%, 6%, 10%, and 14% of energy)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Monounsaturated fatty acids (17%, 14%, 10%, and 6% of energy)
Number of subjects: 63
Study: 2704341

Group type: EXPERIMENTAL
Intervention: Recent aggressive treatment protocols for ALL
Number of subjects: 2093

Group type: EXPERIMENTAL
Intervention: Three-drug reinduction program after consolidation
Number of subjects: 2093
Study: 408433

Group type: EXPERIMENTAL
Intervention: H. influenzae type b polysaccharide vaccine
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: N. meningitidis polysaccharide vaccine
Number of subjects: 16000
Study: 30303934

Group type: EXPERIMENTAL
Intervention: Exercise + Maintenance (E + M)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 55
Study: 27922453

Group type: EXPERIMENTAL
Intervention: Fostemsavir (400 mg twice daily)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Fostemsavir (800 mg twice daily)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Fostemsavir (600 mg once daily)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Fostemsavir (1,200 mg once daily)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Fostemsavir (various doses)
Number of subjects: 251

Group type: COMPARATOR
Intervention: ATV/r (ritonavir-boosted atazanavir 300/100 mg once daily)
Number of subjects: 251
Study: 24571193

Group type: EXPERIMENTAL
Intervention: 12 mg methylnaltrexone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 72
Study: 23079864

Group type: EXPERIMENTAL
Intervention: Hyperoxic (HYP) (FIO2 99.5 %)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normoxic (NORM) (FIO2 21 %)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both HYP and NORM
Number of subjects: 10
Study: 21646646

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily for 6 months
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 19888785

Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ 320mg/25mg
Number of subjects: 1329

Group type: COMPARATOR
Intervention: HCTZ 25mg
Number of subjects: 1329

Group type: COMPARATOR
Intervention: valsartan 320mg
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Combination therapy (valsartan/HCTZ)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1329
Study: 16920896

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1 mg during fasting
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tesaglitazar 1 mg after a high-fat, high-calorie breakfast
Number of subjects: 20
Study: 15545185

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily for 3 years
Number of subjects: 299
Study: 11430152

Group type: EXPERIMENTAL
Intervention: Randomized controlled design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quasi-experimental derivatives
Number of subjects: 0
Study: 9261306

Group type: EXPERIMENTAL
Intervention: Needling (n = 14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medical treatment with aqueous humor suppressants (n = 11)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medical treatment (n = 11)
Number of subjects: 25
Study: 8114057

Group type: EXPERIMENTAL
Intervention: benazepril
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 30
Study: 2951019

Group type: EXPERIMENTAL
Intervention: Danggui Shaoyao powder
Number of subjects: 92
Study: 31288544

Group type: EXPERIMENTAL
Intervention: Singing intervention (n = 31)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Painting intervention (n = 28)
Number of subjects: 59
Study: 29450827

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 462

Group type: COMPARATOR
Intervention: Anastrozole 1 mg
Number of subjects: 462
Study: 27595812

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program (SFP)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Minimal control condition
Number of subjects: 292
Study: 24173028

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (single oral dose of ∼4.4 × 10(8) CFU)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 22851563

Group type: EXPERIMENTAL
Intervention: CRLF2 deregulation (CRLF2‐d)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: IGH@ translocations (IGH@‐t)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: IKZF1 deletions
Number of subjects: 454

Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: CRLF2‐d patients
Number of subjects: 454
Study: 20465002

Group type: EXPERIMENTAL
Intervention: Grifor vaccine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vaxigrip vaccine
Number of subjects: 36
Study: 19186329

Group type: EXPERIMENTAL
Intervention: High fiber BRAN meal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Meals rich in saturated fat, oleic acid, and alpha-linolenic acid
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Meals rich in starch and fiber
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cortisol AUC
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 29
Study: 15912482

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.0 mg
Number of subjects: 36
Study: 12606734

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 10 mg once daily for 48 weeks
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 10947322

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms twice daily) via Pulvinal inhaler
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms twice daily) via Diskhaler inhaler
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both groups (Pulvinal and Diskhaler)
Number of subjects: 72
Study: 8874327

Group type: COMPARATOR
Intervention: 5‐FU 450 mg/m2 as an intravenous bolus with FA 200 mg/m2 in 500 mL 0.9% normal saline solution in 2‐hour infusion (Group A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 5‐FU 450 mg/m2 as an intravenous bolus with FA 200 mg/m2 in 500 mL 0.9% normal saline solution in 2‐hour infusion plus IFN 2b 5 million units subcutaneously three times weekly (Group B)
Number of subjects: 106

Group type: COMPARATOR
Intervention: 5‐FU and FA (Group A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 5‐FU and FA plus IFN 2b (Group B)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: IFN 2b (Group B)
Number of subjects: 106
Study: 2005734

Group type: EXPERIMENTAL
Intervention: Paper diapers
Number of subjects: 141

Group type: COMPARATOR
Intervention: Double cloth diapers with plastic overpants
Number of subjects: 141

Group type: COMPARATOR
Intervention: Clothes worn over diapers
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Rooms with diarrhea occurrences
Number of subjects: 141
Study: 6421004

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion
Number of subjects: 104
Study: 30347425

Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Carcinoembryonic antigen (CEA)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 206
Study: 30071993

Group type: EXPERIMENTAL
Intervention: Ranolazine 1,000 mg twice a day
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012
Study: 25493621

Group type: EXPERIMENTAL
Intervention: 1.25 mg intracameral bevacizumab
Number of subjects: 71

Group type: COMPARATOR
Intervention: Balanced salt solution as placebo
Number of subjects: 71
Study: 25024657

Group type: EXPERIMENTAL
Intervention: Classroom-based sleep education program (4 sessions of 50 minutes each)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 29
Study: 22206782

Group type: EXPERIMENTAL
Intervention: Visual training combined with agility drills
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agility drills only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group following ACSM exercise recommendations
Number of subjects: 0
Study: 19515291

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 53
Study: 18032884

Group type: EXPERIMENTAL
Intervention: Cocoa powder dissolved in water (CC-W)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cocoa powder dissolved in milk (CC-M)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Whole milk (M-c)
Number of subjects: 21
Study: 15068963

Group type: EXPERIMENTAL
Intervention: Marked hyperglycemia (15 mM) during gastric distension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological hyperglycemia (8 mM) during gastric distension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Euglycemia (5 mM) during gastric distension
Number of subjects: 0
Study: 11784454

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily for 12 weeks)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (daily for 12 weeks)
Number of subjects: 111
Study: 9770654

Group type: EXPERIMENTAL
Intervention: Head-only rotational testing (HORT) with visual fixation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head-only rotational testing (HORT) without visual fixation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active head movement during HORT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive head movement during HORT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual fixation during HORT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with healthy young control subjects
Number of subjects: 0
Study: 8149802

Group type: EXPERIMENTAL
Intervention: Lichtenstein patch
Number of subjects: 209

Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 209
Study: 3061823

Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/mq i.v. every 3 weeks) + 5‐fluorouracil (600 mg/mq i.v. bolus/weekly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5‐fluorouracil alone (same schedule)
Number of subjects: 60
Study: 26218236

Group type: EXPERIMENTAL
Intervention: PREG-LT (Pregnenolone 50 mg/day + L-Theanine 400 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27701170

Group type: EXPERIMENTAL
Intervention: Beta-blockers (BBs) at baseline
Number of subjects: 2538

Group type: COMPARATOR
Intervention: Ceftriaxone (intravenous, 2 g per day for 4 days)
Number of subjects: 2538
Study: 23995395

Group type: EXPERIMENTAL
Intervention: Post-treatment (3 months after acute phase)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Post-herpetic neuralgia patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Antiviral therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Epidermal free nerve endings
Number of subjects: 35
Study: 23104856

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 4g/d supplying 1,600mg/d eicosapentaenoic acid and 800mg/d docosahexaenoic acid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 4g/d
Number of subjects: 40